Monday, March 17, 2025 | 03:06 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Syngene International surges 9% on ICMR nod for its Covid-19 test kit

The product will be launched once it receives approval from the Central Drugs Standard Control Organisation (CDSCO) next.

Stock markets, Shares
Premium

The stock had hit an all-time high of Rs 522 on August 26, 2020.

SI Reporter New Delhi
Shares of Syngene International rallied nearly 9 per cent on the BSE on Thursday, a day after the company and HiMedia Laboratories, which have collaborated to manufacture ELISafe 19, an IgG based ELISA test kit for Covid-19, received the approval by the Indian Council of Medical Research (ICMR). 

At 09:52 AM, the stock was trading 8.4 per cent higher at Rs 491.85 on the BSE as compared to a 0.76 per cent rise in the S&P BSE Sensex at 38,483.48 levels. The stock had hit an all-time high of Rs 522 on August 26, 2020. 

The product will be launched

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in